Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Zürich | OTHER |
| Wuerzburg University Hospital | OTHER |
| Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | OTHER |
| Erasmus Medical Center |
Not provided
Not provided
Not provided
Not provided
The differential diagnosis of central diabetes insipidus (cDI) is difficult and the current test with the highest diagnostic accuracy is copeptin measurement after hypertonic saline infusion (HIS). Although the HIS improved diagnostic accuracy compared to the standard water deprivation test used for decades before, it still comprises great discomfort for patients due to the rise in serum sodium levels above 149mmol/l and requires the presence of medical staff at all times to guarantee safety of the test.
The arginine stimulation test is routinely used to stimulate growth hormone. Own data in 52 patients with polyuria / polydipsia syndrome showed that arginine infusion is a potent stimulator of the neurohypophysis and provides a new diagnostic tool in the differential diagnosis of cDI. Copeptin measurements upon arginine stimulation (CAS) discriminated patients with diabetes insipidus vs. patients with primary polydipsia with a high diagnostic accuracy of 94%.
To validate these results and to compare them against the HIS a large multicenter trial is needed, where the diagnostic accuracy of the CAS is compared to the HIS.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arginine Infusion | Experimental | Arginine Stimulation Test |
|
| Hypertonic saline infusion | Active Comparator | Hypertonic Saline Infusion Test |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Arginine infusion | Diagnostic Test | Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| The primary outcome is the overall diagnostic accuracy - defined as the proportion of correct diagnoses - of each diagnostic procedure in differentiating patients with central diabetes insipidus from patients with primary polydipsia. | For Arginine stimulation the copeptin cut-off to differentiate between diabetes insipidus and primary polydipsia will be 3.8 pmol/l after 60 minutes, for hypertonic saline stimulation it will be the copeptin cut-off 4.9 pmol/l taken at the end of the test | 2 days |
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values | Copeptin cut-offs used: Arginine stimulation:
Hypertonic saline stimulation:
|
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mirjam Christ-Crain, Prof, MD | University Hospital, Basel, Switzerland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital das clinicas Minas Gerais | Belo Horizonte | Brazil | ||||
| University Hospital Würzburg |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40294614 | Derived | Atila C, Chifu I, Drummond JB, Vogt DR, Nahum U, Fassnacht M, Winzeler B, Refardt J, Christ-Crain M. A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international multicentre prospective diagnostic studies. Lancet Diabetes Endocrinol. 2025 Jun;13(6):505-515. doi: 10.1016/S2213-8587(25)00053-1. Epub 2025 Apr 25. | |
| 39425917 |
Not provided
Not provided
Not provided
| OTHER |
| Cambridge University Hospitals NHS Foundation Trust | OTHER |
| Federal University of Minas Gerais | OTHER |
Observational randomized cross-over diagnostic international multicenter study
Not provided
Not provided
Not provided
| Hypertonic saline infusion | Diagnostic Test | Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l |
|
| 2 days (1 day for each test, evaluation diagnostic accuracy at end of trial) |
| Specificity of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values | Copeptin cut-offs used: Arginine stimulation:
Hypertonic saline stimulation:
| 2 days (1 day for each test, evaluation diagnostic accuracy at end of trial) |
| Positive predictive value of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values | Copeptin cut-offs used: Arginine stimulation:
Hypertonic saline stimulation:
| 2 days (1 day for each test, evaluation diagnostic accuracy at end of trial) |
| Negative predictive value of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values | Copeptin cut-offs used: Arginine stimulation:
Hypertonic saline stimulation:
| 2 days (1 day for each test, evaluation diagnostic accuracy at end of trial) |
| Best fit diagnostic copeptin cut-off values for differentiation between each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) upon arginine stimulation and hypertonic saline infusion stimulation | 2 days (1 day for each test, evaluation diagnostic accuracy at end of trial) |
| Accuracy of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test | 2 days (1 day for each test, evaluation diagnostic accuracy at end of trial) |
| Sensitivity of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test | 2 days (1 day for each test, evaluation diagnostic accuracy at end of trial) |
| Specificity of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test | 2 days (1 day for each test, evaluation diagnostic accuracy at end of trial) |
| Accuracy of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test | 2 days (1 day for each test, evaluation diagnostic accuracy at end of trial) |
| Sensitivity of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test | 2 days (1 day for each test, evaluation diagnostic accuracy at end of trial) |
| Specificity of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test | 2 days (1 day for each test, evaluation diagnostic accuracy at end of trial) |
| Frequency and severity of thirst assessed by visual analogue scale during both tests | assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms. | 2 days (1 for each test) |
| Frequency and severity of headache assessed by visual analogue scale during both tests | assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms. | 2 days (1 for each test) |
| Frequency and severity of nausea assessed by visual analogue scale during both tests | assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms. | 2 days (1 for each test) |
| Frequency and severity of vertigo assessed by visual analogue scale during both tests | assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms. | 2 days (1 for each test) |
| Frequency and severity of general malaise assessed by visual analogue scale during both tests | assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms. | 2 days (1 for each test) |
| Subjective burden assessed by visual analogue scale of both tests | assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms. | 2 days (1 for each test) |
| Health care costs of both tests | 2 days (1 for each test) |
| Frequency of test preference at follow up visit | 30 days |
| Würzburg |
| Germany |
| Granda Ospedale Maggiore Policlinico Milan | Milan | Italy |
| Erasmus MC | Rotterdam | Netherlands |
| University Hospital Basel, Department of Endocrinology | Basel | Canton of Basel-City | 4031 | Switzerland |
| University Hospital Zurich | Zurich | Switzerland |
| Cambridge University Hospital | Cambridge | United Kingdom |
| Derived |
| Bizzozero CA, Monnerat S, Chapman FA, Dhaun N, Refardt J, Christ-Crain M. Apelin levels in patients with polyuria-polydipsia syndrome upon copeptin stimulation tests. Eur J Endocrinol. 2024 Oct 29;191(5):491-498. doi: 10.1093/ejendo/lvae138. |
| 37966286 | Derived | Refardt J, Atila C, Chifu I, Ferrante E, Erlic Z, Drummond JB, Indirli R, Drexhage RC, Sailer CO, Widmer A, Felder S, Powlson AS, Hutter N, Vogt DR, Gurnell M, Soares BS, Hofland J, Beuschlein F, Fassnacht M, Winzeler B, Christ-Crain M. Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency. N Engl J Med. 2023 Nov 16;389(20):1877-1887. doi: 10.1056/NEJMoa2306263. |
| ID | Term |
|---|---|
| D003919 | Diabetes Insipidus |
| D059607 | Polydipsia, Psychogenic |
| ID | Term |
|---|---|
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D010900 | Pituitary Diseases |
| D004700 | Endocrine System Diseases |
| D059606 | Polydipsia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided